1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Zhejiang Yatai Pharmaceutical Co., Ltd. Class A

Zhejiang Yatai Pharmaceutical Co., Ltd. Class A

SSZSE:002370
4.78
CNY
+0.06
(+1.27%)
0.15EPS
36.45P/E
4.08BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.86
0.93
1.13
1.73
1.69
2.1
1.32
0.94
0.59
0.7
0.71
0.59
0.44
0.46
Basic EPS, GAAP
0.01
0.1
0.14
0.22
0.26
0.28
-3.58
0.05
-0.43
-0.25
-0.02
0.05
0.13
0.15
Free Cash Flow per Basic Share
0.02
-0.05
0.16
-0.26
-0.29
-1.1
-0.65
-0.04
-0.04
-0.02
0.01
0.02
0.03
- -
Dividend per Share
- -
0.01
0.06
0.1
0.05
0.11
0.08
0.03
0.03
0.03
0.03
0.02
0.05
0.05
Book Value per Share
1.74
1.83
1.93
4.02
4.23
4.41
1.18
1.23
0.81
0.56
0.95
1.33
1.5
1.5
Tangible Book Value per Share
1.65
1.69
0.06
2.61
2.82
2.78
0.99
1.02
0.59
0.42
0.84
1.24
1.44
1.44
Basic Weighted Avg Shares
365
406
411
440
537
539
537
545
531
531
594
685
741
744
Sales/Revenue/Turnover
314
376
463
762
907
1,132
709
515
315
373
421
405
323
340
Operating Margin (%)
1.46
12.4
13.57
17.82
17.99
17.5
-17
-11.38
-39.02
-2.45
-6.19
-0.51
-3.79
3.01
Depreciation Expense
24
25
29
39
38
44
53
49
44
42
39
37
32
- -
Net Income, GAAP
5
41
55
97
140
151
-1,921
27
-228
-133
-12
34
96
112
Effective Tax Rate (%)
5.51
16.16
14.39
10.5
14.11
12.62
- -
3.95
- -
- -
- -
0.71
0.13
0.05
Profit Margin (%)
1.75
10.8
11.98
12.7
15.38
13.33
-270.79
5.3
-72.44
-35.53
-2.82
8.45
29.8
32.85
Working Capital
400
394
99
947
907
810
1,309
982
782
782
793
539
746
732
LT Debt
- -
- -
513
- -
100
165
982
933
863
900
639
- -
- -
- -
Total Equity
710
747
793
2,166
2,278
2,376
633
660
433
301
581
972
1,120
1,124
Return on Invested Capital (%)
0.75
5.15
4.64
4.87
6.15
6.08
- -
2.91
- -
- -
- -
2.17
7.46
8.76
Return on Capital (%)
0.85
5.46
5.01
6.26
6.1
6.43
- -
5.52
- -
- -
- -
5.02
10.8
11.88
Return on Common Equity (%)
0.78
5.57
7.24
6.58
6.31
6.52
-128.16
4.22
-41.76
-36.14
-2.69
4.41
9.21
10.55

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
746
746
746
Market Capitalization
5,451
5,540
4,079

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
898
858
795
Cash, Cash Equivalents & STI
619
617
515
Accounts Receivable, Net
91
96
110
Inventories
107
101
92
Total Current Liabilities
152
109
63
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
22.41%
22.11%
15.23%
Free Cash Flow
-16.1%
-14.97%
63.78%
Net Income, GAAP
-262.4%
-255.38%
181.27%
Sales/Revenue/Turnover
1.21%
-6.32%
-20.25%
Total Cash Common Dividend
28.03%
39.58%
214%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
113
109
85
98
405
2025
65
88
- -
95
323
2026
60
98
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.01
-0.01
0.06
0.05
2025
-0.01
0.15
- -
- -
0.13
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
- -
- -
0.02
2025
- -
0.05
- -
- -
0.05
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jian Wei Cen
Full Time Employees
511
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 36, Nanbin West Road Shaoxing ZH China 312366
IPO Date
Mar 17, 2010
Website
ytyaoye.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Zhejiang Yatai Pharmaceutical Co., Ltd. (002370.SZ) researches, develops, manufactures, sells, and exports pharmaceutical products primarily in China and internationally; the company specializes in chemical preparations, active pharmaceutical ingredients, and generic drugs across antibiotic and non-antibiotic categories. Main products include antibiotic offerings such as amoxicillin clavulanate potassium dispersible tablets, azithromycin dispersible tablets, roxithromycin capsules, injectable cefazoxime sodium, and injectable cefumizole sodium; non-antibiotic drugs encompass digestive system medications like injectable pantoprazole sodium, injectable omeprazole sodium, omeprazole enteric capsules, and lansoprazole enteric capsules, as well as antiviral agents including ribavirin injections, aloxivir injections, and aciclovir injections, alongside cardiovascular drugs and antipyretic analgesics; the company also produces tablets, capsules, patches, powder injections, troches, chemical agents, raw materials, and diagnostic reagents, while providing pharmaceutical research and development outsourcing services. Founded in 1989 and headquartered in Shaoxing, Zhejiang Province, China, the company--formerly Zhejiang Asia Pacific Pharmaceutical Factory--completed shareholding system reform in 2001 and listed on the Shenzhen Stock Exchange in 2010; it operates as a national high-tech enterprise targeting domestic hospital networks, retail chains, clinics, and export markets. Recent developments include a March 2025 agreement to transfer 100% equity in subsidiary Shaoxing Xingya Pharmaceutical Co., Ltd. to Zhejiang Zhongqingda Construction Industry Co., Ltd. for CNY 175 million including debt assumption, and an October 2025 share subscription agreement with Zhejiang Xinghao Holding Partnership Enterprise (Limited Partnership) for approximately CNY 700 million via private placement of 136.99 million shares at CNY 5.11 each to fund R&D projects, both pending regulatory approvals.